Mom, Desperate to Help Her Son, Drove the First Cannabis Pharmaceutical to Market – KQED

“He did something that looked like a judo bow after a match,” says Nussenbaum.

Two months passed before Sam had another seizure, but then he started having them every week. Eventually he was suffering through 100 seizures a day.

“When they were bad, they were once every three minutes,” Nussenbaum says.

A Roller-Coaster Ride

Sam was diagnosed with epilepsy with myoclonic-absences, which is characterized by an abrupt unresponsiveness and then sudden body jerks. The episodes were quick, but dangerous.

Dr. Roberta Cilio, neurologist at UCSF, proudly tells her patient Sam Vogelstein he is cleared to drive a car. (Lesley McClurg/ KQED)

The electricity in Sam’s brain would misfire for about five to 20 seconds, enough time to fall down stairs, plunge face first into a dinner plate, or crack his head on a window.

“I don’t remember a lot of it really,” says Sam.

He does remember the barrage of medications his doctors put him on. Some helped briefly. Others triggered hallucinations, full body rashes and uncontrolled anger.

“Sam is a pretty gentle person,” his mother says. “We put him on one medication and it made him angry, and he started punching kids. And it was like, ‘Oh my God, this is not my kid.’ “

More than 3.4 million Americans have epilepsy, according to the Centers for Disease Control and Prevention, but treating the disease is often a riddle doctors find difficult to solve.

Sam struggled to read, to write, to solve math problems, and Nussenbaum watched her son fall further and further behind in school.

Life for Sam was like a bad cell phone connection: Every few moments the signal dropped out.

“It was scary,” Nussenbaum says. “I would often cry in my shower or I would drive up to the top of Grizzly Peak [in Berkeley] and sit in my car and scream.”

Joining the Underground

In 2011, Nussenbaum came across an article in a British medical journal about a small seizure study on rats. The researchers successfully treated the rodents with CBD.

“I thought, ‘My son needs access to that,’ ” says Nussenbaum.

But seven years ago, pure CBD was not easy to get. Many states have since legalized medical marijuana and CBD is widely available at dispensaries and on the internet, but it is still classified as a Schedule 1 drug by the U.S. Drug Enforcement Administration, which means it’s illegal under federal law.

Nussembaum joined an underground epilepsy collective. The group worked with an herbalist to cook up their own CBD. Sam responded well to the first recipe, but his seizures returned while he was medicating with the second batch.

“When we had it tested, there was no CBD,” says Nussembaum.

Next, Sam’s family and another member of the collective tried to make their own CBD.  The process produced a rank odor that wafted out into the neighborhood.

“We talked about what would happen if we get arrested,” said Nussembaum.  “And I thought, you know what, arrest me.”

Pushing for Access

Finally, Nussenbaum learned about a British pharmaceutical company, GW Pharmaceuticals, that was making a medicine derived from highly concentrated CBD to treat multiple sclerosis patients. After months of phone calls and emails from Sam’s parents, the company agreed to let Sam try the drug, in the U.K. and under a doctor’s supervision for two weeks. The family flew to London shortly after.

“After one day his seizures were down to 30,” says Nussenbaum. “After two days they were down to 10. After three days he had one seizure.”

Sam didn’t suffer any side effects.

Back in the U.S., Sam’s parents needed to find a way to keep getting the drug. They collaborated with Dr. Roberta Cilio, a neurologist at UC San Francisco. They petitioned the FDA to allow Sam to use the drug under a compassionate use program. Four months and hundreds of pages of documents later, the FDA allowed Sam to enroll in his own one-person trial at UCSF.

The DEA was a little more cautious. One day two agents knocked on Cilio’s office door. After hours of questioning, the two men requested she store the medication in a giant safe weighing close to 1,000 pounds.

According to GW Pharmaceuticals, Sam was the first patient in the world to receive Epidiolex, the brand name of the purified CBD strain.

An Expanded Trial and Varying Results

Inspired by Sam’s success, Cilio, and other clinicians, started trying Epidiolex on other patients. In 2015, she and several co-authors published a study in Lancet Neurology that included 214 patients with treatment-resistant epilepsy, all children and young adults. (The trial was partly funded by GW Pharmaceuticals.)

Sam Vogelstein at fencing lessons in Berkeley, CA. (Fred Vogelstein)

For most patients the results were not as dramatic as they had been for Sam. Seizures dropped in 36.5 percent of patients, which is about the same success rate as other seizure medications, Cilio says.

And some patients experienced side effects like fatigue, diarrhea and convulsions. Cilio doesn’t know why CBD transforms some lives and other patients don’t respond at all.

“The studies that are out are mostly short term,” says Cilio. “We need to learn who the best responders are. Of course, we know this is not a miracle drug.”

There have been other trials of CBD oil for intractable epilepsy, which have shown that the substance is helpful for a portion of patients, and several states have legalized CBD oil specifically for the treatment of intractable epilepsy or seizure disorders.

CBD has gained popularity with consumers as a remedy for a variety of other ailments. But the products that are available over the counter or in medical cannabis dispensaries aren’t regulated the way pharmaceutical drugs are, so the consistency and dose can vary widely.

The FDA’s decision to approve Epidiolex means that epilepsy patients will have access to a pharmaceutical-grade drug, which delivers a high-quality, consistent dose of CBD, says Robert Carson a pediatric neurologist at Vanderbilt University who treats patients with epilepsy.

Unanswered Questions

Epidiolex still has to get over one regulatory hurdle. The DEA needs to reclassify CBD so it is no longer considered a Schedule 1 substance. Drugs in this category are considered to have no medical use and a high potential for abuse. The FDA’s approval of Epidiolex means CBD no longer fits that category, and the reclassification is expected sometime in the fall.

Patients will need a prescription to get the drug. GW Pharmaceuticals has not released a price yet. And Sam’s mom, Evelyn Nussenbaum, worries that some insurance companies might not cover it.

In the meantime, Sam still gets his drugs from the investigational pharmacy at UCSF. One day he hopes he’ll be prescribing the medication to patients like him.

“I want to be an epilepsy doctor,” Sam says.

Source: https://www.kqed.org/futureofyou/443383/meet-sam-the-berkeley-kid-who-inspired-first-marijuana-based-drug

« »